Effective Antimicrobial Stewardship for Outpatient Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Diseases Physician Infusion Centers

Presented on November 26, 2018

Ramesh V. Nathan, MD, FIDSA – Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA
Richard L Hengel, MD – Atlanta ID Group, Atlanta, GA
Andrew H Krinsky, MD – Infectious Diseases Associates, Sarasota, FL
Thomas K Sleweon, MD – ID Specialists of Indiana, Highland, IN
Alfred E. Bacon, III, MD – Infectious Disease Associates, PA, Newark, DE
K. Dale Hooker, PharmD – Healix Infusion Therapy, Inc., Knoxville, TN
Claudia P Schroeder, PharmD, PhD – Healix Infusion Therapy, Sugar Land, TX
Kimberly Couch, PharmD, MA, FIDSA, FASHP – Healix Infusion Therapy, Inc, Sugar Land, TX
Lucinda J. Van Anglen, PharmD – Healix Infusion Therapy, Inc, Sugar Land, TX

View Abstract

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.